Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVS-233 SR vs Tibolone for Menopausal Vasomotor Symptoms
NCT00195546Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of desvenlafaxine in vasomotor symptoms of menopause (VMS) (3 arms), sponsored by Pfizer. Primary endpoints: Change from baseline in average daily number of moderate to severe hot flashes at 12 weeks, Incidence of uterine bleeding at 12 weeks and 1 more. Started Apr 2005; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
vasomotor symptoms of menopause (VMS)
Beyond the preview
Go deeper on NCT00195546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00195546.